At PhRMA, we often talk about the complexity of developing innovative medicines. Critical to researching new medicines is a workforce that combines sheer brainpower with a level of perseverance unmatched in other industries.
To attract and maintain a strong workforce, we are proud to recognize diversity in the workplace, especially our LGBT colleagues. With today marking the final day of Lesbian, Gay, Bisexual, and Transgender (LGBT) Pride Month, PhRMA is proud to celebrate the diversity of our own and member companies’ LGBT employees by recognizing their important contributions to the drug discovery process.
Diversity in the biopharmaceutical industry is vital as it facilitates openness to new ideas, collaboration and an appreciation of each and every employee’s unique contributions. As a member of the LGBT community myself, I see firsthand how our companies efforts to support inclusion are helping pave the way to new ideas and approaches to researching innovative medicines for patients.
As we close our LGBT PRIDE Month, we celebrate the importance of diversity in each and every employee and patients we serve.
Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organizations scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.